+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Investigation Report on China's Infliximab Market 2021-2025

  • ID: 5331422
  • Report
  • May 2021
  • Region: China
  • 50 Pages
  • China Research & Intelligence


  • Janssen Biologics BV
Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-a) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. By 2020, Janssen Biologics BV is the only manufacturer in the Chinese Infliximab market.

According to the market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.86% in 2020 and reached CNY213.7 million. The CAGR for Infliximab is approximately 14.65% from 2016 to 2020.

The analyst analyzes that the sales of Infliximab will keep a growth trend from 2021 to 2025 due to price reduction. After the patent for Infliximab expired, more biosimilar drugs have appeared on the market. In China, three companies have already submitted applications for Infliximab in 2019 and 2020. Therefore, in the next few years, the market share for Janssen Biologics BV will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Infliximab.

Topics Covered:

  • The impact of COVID-19 on China's Infliximab market
  • Sales value of China's Infliximab 2016-2020
  • Competitive landscape of China's Infliximab market
  • Prices of Infliximab in China
  • Prices of Infliximab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Infliximab market
  • Prospect of China's Infliximab market from 2021 to 2025
Note: Product cover images may vary from those shown


  • Janssen Biologics BV

1 Relevant Concept of Infliximab    
1.1 Indications for Infliximab    
1.2 Development of Infliximab in China    
1.3 Governmental Approval of Infliximab in China
1.4 The Impact of COVID-19 on Infliximab sales in China

2 Sales of Infliximab in China, 2016-2020    
2.1 Sales Value of Infliximab    
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region    
2.2 Sales Volume of Infliximab    
2.2.1 Overall Sales Volume    
2.2.2 Sales Volume by Regions    
2.3 Sales of Infliximab by Dosage Form in China, 2016-2020    
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Infliximab Manufacturers in China, 2016-2020    
3.1 Analysis of Market Share of Major Infliximab Manufacturers    
3.1.1 Investigation on Market Share by Sales Value    
3.1.2 Investigation on Market Share by Sales volume    
3.2 Janssen Biologics BV    
3.2.1 Enterprise Profile    
3.2.2 Sales of REMICADE (Janssen’s Infliximab) in China    

4 Prices of Infliximab for Different Manufacturers in China, 2020-2021
4.1 Janssen Biologics BV (REMICADE)    

5 Prospect of Chinese Infliximab drug Market, 2021-2025
5.1 Influential Factors of Chinese Infliximab Market Development
5.1.1 The Impact of COVID-19 on the Chinese Infliximab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size    
5.3 Forecast on Market Trend    

List of Charts
Chart Patent Information About Infliximab Injection Registration in China
Chart Sales Value of Infliximab Injection over the World    
Chart Sales Value of Infliximab Injection in China, 2016-2020    
Chart Sales Value of Infliximab Injection in China by Regions, 2016-2020
Chart Sales Volume of Infliximab Injection in China, 2016-2020    
Chart Sales Volume of Infliximab Injection in China by Regions, 2016-2020
Chart Market Share by Sales Value of Top Infliximab Manufacturers in China, 2016-2020
Chart Sales Value and Volume of REMICADE in China, 2016-2020          
Chart Referential Prices of REMICADE in China, 2020-2021 
Chart Forecast on Sales Value of Infliximab in China, 2021-2025
Chart Forecast on Sales Volume of Infliximab in China, 2021-2025 

Note: Product cover images may vary from those shown


  • Janssen Biologics BV    
Note: Product cover images may vary from those shown

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.